21st Century Oncology 11% noteholders waive defaults through July 31

By Caroline Salls

Pittsburgh, July 22 –21st Century Oncology, Inc. reached an agreement with holders of a majority of the total principal amount of its 11% senior notes due 2023 to enter into a second supplemental indenture, which will provide a limited default waiver through July 31, according to an 8-K filed Friday with the Securities and Exchange Commission.

The defaults arose from 21st Century Oncology’s failure to furnish the trustee and noteholders or file with the SEC its 10-K for the year ended Dec. 31, 2015 or a 10-Q for the quarter ended March 31.

As consideration for the waiver, the company agreed to pay $2.30 per $1,000 principal amount of notes to all noteholders and to pay specified fees and expenses of the advisers to the consenting noteholders.

According to the 8-K, 21st Century Oncology expects to hold discussions with its credit agreement lenders and the noteholders regarding a further extension of its deadline for delivering the SEC reports, as well as the report for the quarter ended June 30 and a waiver of any related defaults.

21st Century Oncology is a Fort Myers, Fla.-based provider of integrated cancer care services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.